Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 14, 2006 | Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 9,000 | -- | 179,082 | |
| Aug 12, 2021 | Director, President and CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 9,021 | $27.29 | 369,533 | |
| Jan 19, 2011 | Director, President & CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 9,094 | $16.56 | 109,276 | |
| Feb 14, 2006 | Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 9,100 | $4.35 | 22,889 | |
| Feb 14, 2006 | Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 9,100 | -- | 219,082 | |
| Jul 20, 2022 | SVP and General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 9,283 | -- | 9,283 | |
| Jul 20, 2022 | SVP/GM, Vascular Access | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 9,341 | -- | 9,341 | |
| Aug 15, 2006 | VP - Product Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 9,378 | -- | 9,378 | |
| Aug 12, 2021 | EVP and CFO | Form 4/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 9,437 | -- | -- | |
| Jul 18, 2018 | SVP and General Counsel | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 9,437 | -- | 9,437 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.